384 results on '"Lang, Ninian N"'
Search Results
2. Socioeconomic deprivation and illness trajectory in the Scottish population after COVID-19 hospitalization
3. Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology
4. Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials
5. Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial
6. Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores
7. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial
8. Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: JACC: CardioOncology Primer
9. Hypertension and renal disease prevention before cancer therapy
10. Contributors
11. Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography
12. Response by Henriksen et al Regarding Article, “Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial”
13. Measuring congestion with a non‐invasive monitoring device in heart failure and haemodialysis: CONGEST‐HF
14. Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS‐MI): rationale and design
15. A multisystem, cardio-renal investigation of post-COVID-19 illness
16. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial
17. Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review
18. Intravenous iron and SGLT2 inhibitors in iron‐deficient patients with heart failure and reduced ejection fraction.
19. Cardiovascular Oncologic Emergencies
20. Nailfold video-capillaroscopy in the study of cardiovascular disease: a systematic review
21. Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study
22. Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study
23. Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer.
24. Antihypertensive Drugs and Vascular Health
25. Vascular Biology of Cancer Chemotherapeutic Drugs
26. Comprehensive Characterization of the Vascular Effects of Cisplatin-Based Chemotherapy in Patients With Testicular Cancer
27. Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer
28. Reply
29. Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial
30. Kidney Disease Patient Representation in Trials of Combination Therapy With VEGF-Signaling Pathway Inhibitors and Immune Checkpoint Inhibitors: A Systematic Review
31. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics
32. Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation
33. Antihypertensive Drugs and Vascular Health
34. Progressive Hypertension and Severe Left Ventricular Outflow Tract Obstruction
35. Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients
36. Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction
37. Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials
38. A multicenter prospective randomized controlled trial of high sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: the Cardiac CARE trial
39. Temporal trends in the incidence of malignancy in heart failure:a nationwide Danish study
40. Vascular Complications of Cancer Chemotherapy
41. Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study
42. Cardiac geometry, as assessed by cardiac magnetic resonance, can differentiate subtypes of chronic thromboembolic pulmonary vascular disease
43. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction
44. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: associations with mortality in a haemodialysis cohort
45. A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes
46. Nailfold video-capillaroscopy in the study of cardiovascular disease: a systematic review
47. Reference Ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and Risk Factors for Higher NT-proBNP Concentrations in a Large General Population Cohort
48. Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies
49. Rationale and design of a randomised trial of intravenous iron in patients with heart failure
50. 32 - Hypertension and renal failure prevention and management after cancer therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.